Genocea to Present at Two March Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 6/25/2026

1. MU
2. QCOM
3. CBRS
4. FDX
5. USO

6. HTZ
7. SPY
8. KBH
9. HON
10. PFE

Get Alerts GNCA Hot Sheet

Price: $0.05 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at two upcoming investor conferences:

Cowen and Company 38th Annual Health Care ConferenceMonday, March 12, 2018 at 11:20 AM ET in Boston, Massachusetts

Needham & Co. Annual Healthcare ConferenceTuesday, March 27, 2018 at 10:30 AM ET in New York, New York

A live webcast of both presentations can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcasts will be archived for 30 days following the conference.

About Genocea Biosciences, Inc.Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. Genocea is exploring strategic alternatives for GEN-003, its Phase 3-ready immunotherapy candidate for the treatment of genital herpes. For more information, please visit www.genocea.com.

For media:Jennifer LaVinO: 617-715-6687[email protected]

For investors:Jonathan PooleO: 617-876-8191[email protected]